Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2

Vaccine

Volumn 32, Issue 23, 2014, Pages 2675-2681

  Yang, Dong ^a,b   Li, Xiao Feng ^b   Ye, Qing ^b   Wang, Hong Jiang ^b   Deng, Yong Qiang ^b   Zhu, Shun Ya ^b   Zhang, Yu ^b   Li, Shi Hua ^b   Qin, Cheng Feng ^b  

^a XINJIANG AGRICULTURAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Genetic stability; Japanese encephalitis virus; Live attenuated vaccine; Serial passaging; Virulence

Indexed keywords

CAPSID PROTEIN; JAPANESE ENCEPHALITIS VACCINE; LEUCINE; LIVE VACCINE; SERINE; VIRUS ENVELOPE PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; JAPANESE ENCEPHALITIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SUCKLING ANIMAL; VERO CELL LINE; VIRUS MUTATION; VIRUS PLAQUE; VIRUS STRAIN; VIRUS VIRULENCE;

GENETIC STABILITY; JAPANESE ENCEPHALITIS VIRUS; LIVE ATTENUATED VACCINE; SERIAL PASSAGING; VIRULENCE;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; ENCEPHALITIS VIRUS, JAPANESE; GENOME, VIRAL; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; MUTATION; SERIAL PASSAGE; VACCINES, ATTENUATED; VERO CELLS; VIRAL PLAQUE ASSAY; VIRULENCE;

EID: 84899965441     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.074     Document Type: Article

References (45)

1. Hollidge B.S., Gonzalez-Scarano F., Soldan S.S. Arboviral encephalitides: transmission, emergence, and pathogenesis. J Neuroimmune Pharmacol: Off J Soc Neuroimmune Pharmacol 2010, 5:428-442.
2. Mackenzie J.S., Johansen C.A., Ritchie S.A., van den Hurk A.F., Hall R.A. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 2002, 267:49-73.
3. Endy T.P., Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002, 267:11-48.
4. Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 2010, 28:3635-3641.
5. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001, 358:791-795.
6. Gatchalian S., Yao Y., Zhou B., Zhang L., Yoksan S., Kelly K., et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008, 26:2234-2241.
7. Hennessy S., Liu Z., Tsai T.F., Strom B.L., Wan C.M., Liu H.L., et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996, 347:1583-1586.
8. Kumar R., Tripathi P., Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009, 360:1465-1466.
9. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com. Vaccine 2007, 25:5041-5045.
10. Domingo E., Sheldon J., Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev: MMBR 2012, 76:159-216.
11. Ye Q., Li X.F., Zhao H., Li S.H., Deng Y.Q., Cao R.Y., et al. A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation. J Gen Virol 2012, 93:1959-1964.
12. Wang H.J., Li X.F., Ye Q., Li S.H., Deng Y.Q., Zhao H., et al. Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice. Vaccine 2014, 32:949-956.
13. Li X.F., Deng Y.Q., Yang H.Q., Zhao H., Jiang T., Yu X.D., et al. A chimeric dengue virus vaccine using japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 2013, 87:13694-13705.
14. Montagnon B., Vincent-Falquet J. Experience with the Vero cell line. Safety of Biological Products Prepared from Mammalian Cell Culture 1998, 93:119-123. Karger, Basel.
15. Kollaritsch H., Paulke-Korinek M., Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther 2009, 9:921-931.
16. Li X.F., Zhao W., Lin F., Ye Q., Wang H.J., Yang D., et al. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2. J Gen Virol 2013, 94(Pt 12):2700-2709.
17. Eckels K.H., Yu Y.X., Dubois D.R., Marchette N.J., Trent D.W., Johnson A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988, 6:513-518.
18. Dokland T., Walsh M., Mackenzie J.M., Khromykh A.A., Ee K.H., Wang S. West Nile virus core protein; tetramer structure and ribbon formation. Structure 2004, 12:1157-1163.
19. Ma L., Jones C.T., Groesch T.D., Kuhn R.J., Post C.B. Solution structure of dengue virus capsid protein reveals another fold. Proc Nat Acad Sci USA 2004, 101:3414-3419.
20. Schlick P., Taucher C., Schittl B., Tran J.L., Kofler R.M., Schueler W., et al. Helices alpha2 and alpha3 of West Nile virus capsid protein are dispensable for assembly of infectious virions. J Virol 2009, 83:5581-5591.
21. Patkar C.G., Jones C.T., Chang Y.H., Warrier R., Kuhn R.J. Functional requirements of the yellow fever virus capsid protein. J Virol 2007, 81:6471-6481.
22. Kofler R.M., Heinz F.X., Mandl C.W. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. J Virol 2002, 76:3534-3543.
23. Blaney J.E., Johnson D.H., Firestone C.Y., Hanson C.T., Murphy B.R., Whitehead S.S. Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J Virol 2001, 75:9731-9740.
24. Blaney J.E., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002, 300:125-139.
25. Blaney J.E., Manipon G.G., Firestone C.Y., Johnson D.H., Hanson C.T., Murphy B.R., et al. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine 2003, 21:4317-4327.
26. Pletnev A.G., Putnak R., Speicher J., Wagar E.J., Vaughn D.W. West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Nat Acad Sci USA 2002, 99:3036-3041.
27. Tang W.F., Eshita Y., Tadano M., Morita K., Makino Y. Molecular basis for adaptation of a chimeric dengue type-4/Japanese encephalitis virus to Vero cells. Microbiol Immunol 2005, 49:285-294.
28. Beasley D.W., Morin M., Lamb A.R., Hayman E., Watts D.M., Lee C.K., et al. Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes. Virus Res 2013, 176:280-284.
29. Anez G., Men R., Eckels K.H., Lai C.J. Passage of dengue virus type 4 vaccine candidates in fetal rhesus lung cells selects heparin-sensitive variants that result in loss of infectivity and immunogenicity in rhesus macaques. J Virol 2009, 83:10384-10394.
30. McMinn P.C., Marshall I.D., Dalgarno L. Neurovirulence and neuroinvasiveness of Murray Valley encephalitis virus mutants selected by passage in a monkey kidney cell line. J Gen Virol 1995, 76(Pt 4):865-872.
31. Seligman S.J. Constancy and diversity in the flavivirus fusion peptide. Virol J 2008, 5:27.
32. Allison S.L., Schalich J., Stiasny K., Mandl C.W., Heinz F.X. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 2001, 75:4268-4275.
33. Nybakken G.E., Nelson C.A., Chen B.R., Diamond M.S., Fremont D.H. Crystal structure of the West Nile virus envelope glycoprotein. J Virol 2006, 80:11467-11474.
34. Luca V.C., AbiMansour J., Nelson C.A., Fremont D.H. Crystal structure of the Japanese encephalitis virus envelope protein. J Virol 2012, 86:2337-2346.
35. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.X., Monath T.P., Chambers T.J. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 2001, 75:934-942.
36. Zhao Z., Date T., Li Y., Kato T., Miyamoto M., Yasui K., et al. Characterization of the E-138 (Glu/Lys) mutation in Japanese encephalitis virus by using a stable, full-length, infectious cDNA clone. J Gen Virol 2005, 86:2209-2220.
37. Zhang S., Li L., Woodson S.E., Huang C.Y., Kinney R.M., Barrett A.D., et al. A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. Virology 2006, 353:35-40.
38. Liang J.J., Liao C.L., Liao J.T., Lee Y.L., Lin Y.L. A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. Vaccine 2009, 27:2746-2754.
39. Sumiyoshi H., Tignor G.H., Shope R.E. Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis 1995, 171:1144-1151.
40. Chen L.K., Lin Y.L., Liao C.L., Lin C.G., Huang Y.L., Yeh C.T., et al. Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 1996, 223:79-88.
41. Lee E., Hall R.A., Lobigs M., Common E. protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses. J Virol 2004, 78:8271-8280.
42. Knowles M.K., Roberts D., Craig S., Sheen M., Nadin-Davis S.A., Wandeler A.I. In vitro and in vivo genetic stability studies of a human adenovirus type 5 recombinant rabies glycoprotein vaccine (ONRAB). Vaccine 2009, 27:2662-2668.
43. Lee H.C., Yen Y.T., Chen W.Y., Wu-Hsieh B.A., Wu S.C. Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice. PLoS One 2011, 6:e25800.
44. Laassri M., Meseda C.A., Williams O., Merchlinsky M., Weir J.P., Chumakov K. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene. J Med Virol 2007, 79:791-802.
45. Rima B.K., Gatherer D., Young D.F., Norsted H., Randall R.E., Davison A.J. Stability of the parainfluenza virus 5 genome revealed by deep sequencing of strains isolated from different hosts and following passage in cell culture. J Virol 2014, 88:3826-3836.